A new long acting formulation of the luteinizing hormone-releasing hormone analogue, goserelin: Results of studies in prostate cancer

Journal of Urology

Volumn 155, Issue 4, 1996, Pages 1352-1354

  Debruyne, F M ^a   Dijkman, G A ^b   Lee, D C H ^b   Witjes, W P J ^b   Fernandez Del Moral, P ^b   Karthaus, H F M ^b   Van Der Meijden, A P M ^b   Plasman, J W M H ^b   Pull, H C ^b   Kums, J J ^b   Idema, J G ^b   Hoefakker, J W ^b   Heijbroek, R P ^b   Kil, P J M ^b   Khoe, G S S ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

delayed action preparations; goserelin; prostate; prostatic neoplasms; testosterone

Indexed keywords

GOSERELIN;

ADVANCED CANCER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG FORMULATION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; TESTOSTERONE BLOOD LEVEL;

EID: 9044254923     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)66264-5     Document Type: Article

References (8)

1. Boring, C. C., Squires, T. S., Tong, T. and Montgomery, S.: Cancer statistics. CA, 44: 7, 1994.
2. Kaisary, A. V., Tyrrell, C. J., Peeling, W. B. and Griffiths, K.: Comparison of LHRH analogue (Zoladex) with orchidectomy in patients with metastatic prostate carcinoma. Study Group. Brit. J. Urol., 67: 502, 1991.
3. Waymont, B., Lynch, T. H., Dunn, J. A., Emtage, L. A., Arkell, D. G., Wallace, D. M. A. and Blackledge, G. R. P.: Phase III randomised study of Zoladex versus stilboestrol in the treatment of advanced prostate cancer. Brit. J. Urol., 69:614, 1992.
4. Chadwick, D. J., Gillatt, D. A. and Gingell, J. C.: Medical or surgical orchidectomy: the patients' choice. Brit. Med. J., 9: 572, 1991.
5. Samdal, F., Vada, K., Lundmo, P. I. and Mjølnerød, O. K.: Orchidectomy or LHRH-analogue? Which do the patients prefer and what treatment would Norwegian urologists prefer if they had advanced cancer of the prostate? Scand. J. Urol. Nephrol., 25: 197, 1991.
6. Cassileth, B. R., Soloway, M. S., Vogelzang, N. J., Schellhammer, P. S., Seidom, E. J., Hait, H. I. and Kennealey, G. T.: Patient's choice of treatment in stage D prostate cancer. Urology, suppl., 33: 57, 1989.
7. Parmar, H., Phillips, R. H., Lightman, S. L. and Edwards, L.: How would you like to have an orchidectomy for advanced prostatic cancer? Amer. J. Clin. Oncol., suppl. 2, 11: S160, 1988.
8. Debruyne, F. M. J., Denis, L., Lunglmayr, G., Mahler, C., Newling, D. W. W., Richards, B., Robinson, M. R. G., Smith, P. H., Weil, E. H. J. and Whelan, P.: Long-term therapy with a depot luteinizing hormone-releasing hormone analogue (Zoladex) in patients with advanced prostatic carcinoma. J. Urol., 140: 775, 1988.